Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity

Anti-CD52 therapy has been shown to be effective in the treatment of a number of B cell malignancies, hematopoietic disorders and autoimmune diseases (including rheumatoid arthritis and multiple sclerosis); however the current standard of treatment, the humanized monoclonal antibody alemtuzumab, is...

Descripción completa

Detalles Bibliográficos
Autores principales: Holgate, Robert G. E., Weldon, Richard, Jones, Timothy D., Baker, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570798/
https://www.ncbi.nlm.nih.gov/pubmed/26372145
http://dx.doi.org/10.1371/journal.pone.0138123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570798/
https://www.ncbi.nlm.nih.gov/pubmed/26372145
http://dx.doi.org/10.1371/journal.pone.0138123

Ejemplares similares